Inhalation anaesthesia: from diethyl ether to xenon.

Inhalation anaesthesia: from diethyl ether to xenon. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inhalation anaesthesia: from diethyl ether to xenon. Abstract Text:

J G Bovill,J G Bovill,J G Bovill,

Modern anaesthesia is said to have began with the successful demonstration of ether anaesthesia by William Morton in October 1846, even though anaesthesia with nitrous oxide had been used in dentistry 2 years before. Anaesthesia with ether, nitrous oxide and chloroform (introduced in 1847) rapidly became commonplace for surgery. Of these, only nitrous oxide remains in use today. All modern volatile anaesthetics, with the exception of halothane (a fluorinated alkane), are halogenated methyl ethyl ethers. Methyl ethyl ethers are more potent, stable and better anaesthetics than diethyl ethers. They all cause myocardial depression, most markedly halothane, while isoflurane and sevoflurane cause minimal cardiovascular depression. The halogenated ethers also depress the normal respiratory response to carbon dioxide and to hypoxia. Other adverse effects include hepatic and renal damage. Hepatitis occurs most frequently with halothane, although rare cases have been reported with the other agents. Liver damage is not caused by the anaesthetics themselves, but by reactive metabolites. Type I hepatitis occurs fairly commonly and takes the form of a minor disturbance of liver enzymes, which usually resolves without treatment. Type II, thought to be immune-mediated, is rare, unpredictable and results in a severe fulminant hepatitis with a high mortality. Renal damage is rare, and was most often associated with methoxyflurane because of excessive plasma fluoride concentrations resulting from its metabolism. Methoxyflurane was withdrawn from the market because of the high incidence of nephrotoxicity. Among the contemporary anaesthetics, the highest fluoride concentrations have been reported with sevoflurane, but there are no reports of renal dysfunction associated with its use. Recently there has been a renewed interest in xenon, one of the noble gases. Xenon has many of the properties of an ideal anaesthetic. The major factor limiting its more widespread is the high cost, about 2,000 times the cost of nitrous oxide.

Inhalation anaesthesia: from diethyl ether to xenon. Publishing Authors By Initials

JG Bovill,JG Bovill,JG Bovill,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Inhalation anaesthesia: from diethyl ether to xenon. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Handbook of experimental pharmacology

VOLUME:

Page Numbers: 121-42

Journal Abbreviation: Handb Exp Pharmacol

ISSN: 0171-2004

DAY: 4

MONTH: 01

YEAR: 2008

Inhalation anaesthesia: from diethyl ether to xenon. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7902231

Inhalation anaesthesia: from diethyl ether to xenon. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Inhalation anaesthesia: from diethyl ether to xenon. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Inhalation anaesthesia: from diethyl ether to xenon.

AFFILIATION: Department of Anaesthesiology, Leiden University Medical Centre, Leiden, The Netherlands, j.g.bovill@lumc.nl.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Handb Exp Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inhalation anaesthesia: from diethyl ether to xenon Related Publications

• A genetic basis for the interrelation of coagulation factors.
• Anesthetic pharmacology: reflections of a section editor.
• Computed tomography of musculoskeletal disorders.
• Diffuse idiopathic skeletal hyperostosis as an overlooked cause of dysphagia: a case report.
• Exclusion of the alpha2 subunit of platelet-activating factor acetylhydrolase 1b (PAFAH1B2) as a prothrombotic gene in a protein C-deficient kindred and population-based case-control sample.
• Gene discovery in venous thrombosis: progress and promise.
• Inhalation anaesthesia: from diethyl ether to xenon.
• Injury Rates And Risk Factors Among Infantry, Artillery, Construction Engineers, And Special Forces Soldiers: 2185: Board #98 June 1 8:00 AM -9:30 AM.
• Linkage analysis for three coagulation factors clustering on chromosome 13q34: factor VII, factor X and protein Z.
• Novel isoforms of intracellular platelet activating factor acetylhydrolase (PAFAH1b2) in human testis; encoded by alternatively spliced mRNAs.
• SELDI-TOF plasma profiles distinguish individuals in a protein C-deficient family with thrombotic episodes occurring before age 40.
• Transplantable osteogenic sarcoma of the mouse exposed to vitamin A intoxication and vitamin D deficiency.